Mandibular Reconstruction with Tissue Engineering in Multiple Recurrent Ameloblastoma

Federico Hernández-Alfaro, MD, DDS, PhD*  
Vanessa Ruiz-Magaz, DMD**/Punjamun Chatakun, DDS***  
Raquel Guijarro-Martínez, MD****

An ameloblastoma is a tumor of odontogenic epithelial origin. It represents approximately 1% of all cysts and tumors of the maxillofacial region.1,2 Although its cellular features categorize it as benign, it may be locally aggressive—causing severe facial deformity and functional impairment—and highly recurrent.3 The most commonly affected sites are the posterior body and angle of the mandible.4,5 Adequate treatment requires thorough surgical resection of the tumor as well as a functionally and esthetically acceptable reconstruction of the residual defect.3 Soft tissue loss must be minimized; however, incomplete resection of the primary lesion leads to a high risk of recurrence. Several reconstructive options have been proposed, but the corticocancellous block graft is still considered the method of choice for defects less than 5 cm. These grafts tend to be harvested from the anterior or posterior iliac crest with survival rates dependent on the rate of graft revascularization. In addition, micromovements of the graft jeopardize its viability.6

*Oral and Maxillofacial Surgeon and Head, Institute of Maxillofacial Surgery and Implantology, Teknon Medical Center, Barcelona, Spain; Clinical Professor of Oral and Maxillofacial Surgery and Director, Master in Implant Dentistry, Universitat Internacional de Catalunya, Barcelona, Spain.
**Periodontist, Institute of Maxillofacial Surgery and Implantology, Teknon Medical Center, Barcelona, Spain; Associate Professor of Periodontics, Universitat Internacional de Catalunya, Barcelona, Spain.
***Fellow, International Master Program in Implantology, Universitat Internacional de Catalunya, Barcelona, Spain.
****Fellow, Institute of Maxillofacial Surgery and Implantology, Teknon Medical Center, Barcelona, Spain.

Correspondence to: Dr Federico Hernández-Alfaro, Institute of Maxillofacial Surgery and Implantology, Teknon Medical Center, Vilana, 12, D-18S, 01022 Barcelona, Spain; email: director@institutomaxilofacial.com.
Microvascular bone grafting shows higher success rates for defects that are greater than 5 cm in size. The fibula flap is considered the gold standard for mandibular reconstruction; however, microvascular reconstruction is often technically demanding and time-consuming, may cause significant morbidity both at donor and recipient sites, and requires general anesthesia and hospitalization. Further, the quality and height of the bone graft is frequently limited. These drawbacks have led to the development of reconstructive procedures based on tissue engineering.

Tissue engineering blends regenerative medicine and surgery, with its three basic components being scaffolds, cells, and signaling molecules. Tissue regeneration and functional restoration are achieved through the implantation of cells and tissues developed outside the body or the promotion of cell growth in an implanted matrix. These procedures eliminate the need to harvest tissue from a donor site, thereby eradicating concomitant donor site morbidity.

Bone morphogenetic proteins (BMPs) are multifunctional proteins with a wide range of biologic activities involving a variety of cell types. According to the scientific literature, BMPs mediate in cell growth regulation, differentiation, chemotaxis, and apoptosis and play pivotal roles in morphogenesis. Implantation of this protein component of bone matrix results in a complex series of cellular events, including mesenchymal cell infiltration, cartilage formation, vascularization, bone formation, and ultimately, remodeling of the new bone tissue along with population by hematopoietic bone marrow elements.

In 2004, Warnke et al reported a case of mandibular reconstruction with a titanium mesh cage filled with bone mineral blocks, 7 mg of recombinant bone morphogenetic protein 7 (rBMP-7), and 20 mL of the patient’s bone marrow. The reconstruction was implanted into the latissimus dorsi muscle and then transferred to repair the mandibular defect. This technique provided a good three-dimensional outcome.

The aim of this article is to report a case of recurrent ameloblastoma in which mandibular reconstruction was achieved with bovine hydroxyapatite blocks and BMP-7 in combination with bone marrow aspirate concentrate.

Case report

A 33-year-old woman was referred to the authors’ institute with a diagnosis of recurrent ameloblastoma. The patient had been initially diagnosed 2 years earlier, and conservative treatment (extensive curettage) had been applied at that time at a different facility. Tumor recurrence was detected 11 months later, and the patient was subsequently referred to the authors’ institute for radical treatment.

A cone beam computed tomography (CBCT) evaluation revealed an expansive lesion in the left mandibular body with cortical penetration and involvement of a neighboring dental implant (Fig 1). The surgical plan included mandibular segmentectomy with safety margins to avoid further recurrences and a reconstructive procedure. Regarding the latter, the patient refused a free bone graft from the iliac crest and a microvascularized flap from the same donor site. Reconstruction with tissue engineering techniques was thus proposed.

Preoperative work-up included a stereolithographic cast on which a titanium mesh tray was adapted (Fig 2).

Surgery was performed under general anesthesia. An extraoral submandibular 4-cm incision was chosen to minimize the risk of contaminating the reconstruction. Segmental mandibular resection was performed using a reciprocating saw with a safety margin of 1 cm at each side (Fig 3). Therefore, a 6-cm defect was created. The reconstruction was prepared within the preformed titanium mesh using protein demineralized bovine blocks (Bio-Oss, Geistlich) infused with 2 g of rBMP-7 and 5 mL of concentrate from a bone marrow aspirate. To obtain the marrow-derived mesenchymal cell concentration, the iliac crest was perforated approximately 3 cm laterocaudally from the superior posterior iliac spine using a bone marrow biopsy needle. With three 20-mL syringes containing 0.3 mL of heparin solution diluted with sodium chloride to 1,000 U/mL each, 40 mL of bone marrow was collected. The aspirate was pooled and anticoagulated with 3.5 mL of heparin solution.
According to the manufacturer’s instructions, bone marrow cells were isolated directly in the operating room using the BMCA system (Bone Marrow Procedure Pack, Harvest Technologies). To avoid fibrous tissue ingrowth, four bioabsorbable collagen membranes (Bio-Gide, Geistlich) were used (Fig 4). The tissue-engineered reconstruction was then stabilized with screws to bridge the defect, and wound closure was achieved in three layers (Fig 5).

Postoperative recovery was uneventful. A postoperative CBCT confirmed adequate reconstruction of the defect (Fig 6). The pathology report was consistent with the diagnosis of ameloblastoma, and the resection margins were free of tumor invasion.

Nine months later, reentry for implant placement allowed for the harvesting of two cores for histologic analysis. Three 4 × 13-mm Osseotite implants (Biomet 3i) were inserted (two implants in the reconstructed area) (Fig 7). Histologic analysis of the cores harvested at implant insertion revealed new bone formation around the particles of xenograft material (Fig 8). Four months later, the implants were loaded with a fixed prosthesis. At the 1-year follow-up, the implants remained stable (Fig 9).

Discussion

At present, autogenous bone represents the gold standard for hard tissue regeneration. Alternative options include allogenic or xenogenic bone substitutes. The advent of tissue engineering has allowed for the upgrading of standard treatment options, but the efficacy of tissue-engineering techniques depends on the particular method and grafting material used. In the present report, a large critical-sized defect was repaired with bone marrow aspirate seeded on a scaffold obtained from bovine hydroxyapatite blocks, and BMP-7 served as an osteoinductive medium.
There is recent evidence proving the efficacy of BMPs. In terms of osteogenesis and osseous defect repair, growth factors seem to have the highest efficacy. Regarding safety, minor side effects, including headaches, an increase and modification of plasma amylase levels without pancreatitis, and a decrease in magnesium and tachycardia, have been reported in accordance with BMP use. The generation of anti-BMP or anticollagen antibodies has been detected in less than 4% of the population, with no clinically significant consequences.

BMP-7, also known as osteogenic protein 1 (OP-1), has proven its osteoinductive capacity both in experimental and clinical trials. It has been used in combination with a type I collagen carrier for the treatment of tibial nonunions, and clinical and radiographic results comparable to the autogenous bone control group have been reported. All new bone induced by any bone grafting material or osteogenic molecule, including BMP-7, may be considered of autogenous origin and is prone to normal bone remodeling.

In clinical use, bone growth factors need a carrier. Many types of scaffolding have been developed to maintain BMP levels for a long period. Animal studies have shown efficient regeneration of critical-sized defects with recombinant forms of BMP combined with collagen carriers such as guanidine-extracted demineralized bone matrix, hydroxyapatite, or biodegradable polymers.

Bone marrow–derived stem and progenitor cells have been used to regenerate several tissues, including bone. Their use as bone marrow aspirate concentrate is a promising alternative to conventional autogenous grafting. A recent prospective study in the field of orthopedic surgery has shown bone marrow aspirate concentrate combined with biomaterials (porous hydroxyapatite and β-tricalcium phosphate) generates bone trabeculae and a lamellar pattern in spinal fusion surgery.

In this patient, bone marrow aspirate seeded on a scaffold obtained from bovine hydroxyapatite...
blocks (soaked in bone marrow concentrate for 10 minutes) and BMP-7 gave way to new bone formation that was confirmed histologically. The patient presented sufficient bone for implant placement and stable results after 1 year of loading.

Conclusion

Tissue engineering can be a valid alternative to conventional mandibular reconstruction techniques, decreasing patient morbidity and surgical time and thus increasing patient acceptance of the procedure. According to the results of this clinical evaluation, bone marrow aspirate seeded on a scaffold obtained from bovine hydroxyapatite blocks and BMP-7 achieves new bone formation with sufficient quantity and quality to allow for implant placement. Despite this promising preliminary outcome, further clinical assessment is mandatory.

References